About pfizer inc. - PFE
PFE At a Glance
| Phone | 1-212-733-2323 | Revenue | 63.63B | |
| Industry | Pharmaceuticals: Major | Net Income | 8.02B | |
| Sector | Health Technology | 2024 Sales Growth | 8.772% | |
| Fiscal Year-end | 12 / 2025 | Employees | 81,000 | |
| View SEC Filings |
PFE Valuation
| P/E Current | 18.133 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 18.829 |
| Price to Sales Ratio | 2.377 |
| Price to Book Ratio | 1.705 |
| Price to Cash Flow Ratio | 11.866 |
| Enterprise Value to EBITDA | 8.428 |
| Enterprise Value to Sales | 3.112 |
| Total Debt to Enterprise Value | 0.338 |
PFE Efficiency
| Revenue/Employee | 785,518.519 |
| Income Per Employee | 99,012.346 |
| Receivables Turnover | 5.551 |
| Total Asset Turnover | 0.289 |
PFE Liquidity
| Current Ratio | 1.171 |
| Quick Ratio | 0.919 |
| Cash Ratio | 0.476 |
PFE Profitability
| Gross Margin | 65.768 |
| Operating Margin | 25.906 |
| Pretax Margin | 12.609 |
| Net Margin | 12.605 |
| Return on Assets | 3.646 |
| Return on Equity | 9.051 |
| Return on Total Capital | 5.168 |
| Return on Invested Capital | 5.328 |
PFE Capital Structure
| Total Debt to Total Equity | 75.953 |
| Total Debt to Total Capital | 43.167 |
| Total Debt to Total Assets | 31.394 |
| Long-Term Debt to Equity | 67.675 |
| Long-Term Debt to Total Capital | 38.462 |
Pfizer Inc. in the News
Kansas sues Pfizer over 'misrepresentations' and 'adverse events' of COVID-19 vaccine
The State of Kansas has filed a lawsuit against Pfizer, Inc. for alleged consumer protection violations related to the company's manufacturing of the COVID-19 vaccine.
Left-wing activism rampant in corporate shareholder proposal process: report
A Securities and Exchange Commission process for approving shareholder proposals favors a left-wing bent in corporate policies, claims a watchdog, citing audits from 2018-2022.
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Pfizer expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 after most patients treated for a form of lung cancer had no disease progression after five years.
Pfizer shares sink after it resets 2024 COVID expectations
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low.
Pfizer CEO slams presidents of elite colleges over ‘despicable’ antisemitism
Pfizer CEO Albert Bourla criticized the "despicable" testimony of three elite university presidents who were "hiding behind calls for 'context'" before deeming such rhetoric impermissible.
Pfizer scraps twice-daily weight loss pill danuglipron after study shows ‘high rates’ of adverse side effects
Pfizer is shelving development of a twice-daily version of its weight loss drug after a trial proved users reported high rates of adverse side effects.
Texas Attorney General Ken Paxton sues Pfizer, alleges pharma giant lied about COVID vaccine efficacy
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer, alleging that the pharmaceutical giant lied about the effectiveness of its COVID-19 vaccine.
Wall Street CEOs demand Biden and Congress fix NYC migrant crisis
More than 100 CEOs and business leaders in New York City are calling for federal action to fix the United States' broken immigration system and address the migrant crisis.
Vaccine makers see stock price boost on Biden admin COVID shot push
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday.
Conservatives call out multinational corporations for supporting pride month in America, but not Middle East
Conservatives on Twitter are calling out multinational corporations for displaying a pride flag-theamed logo on American social media accounts, but not for those overseas.